⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.91
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.58
−0.85%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,113.16
−0.67%
Brent
$111.32
+1.92%
BTC
$81,251.96
−0.72%
ETH
$2,379.23
−1.08%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.91
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.58
−0.85%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,113.16
−0.67%
Brent
$111.32
+1.92%
BTC
$81,251.96
−0.72%
ETH
$2,379.23
−1.08%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Open
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NYSE
› ABBV
A
AbbVie Inc
NYSE:ABBV
Healthcare
CBOE:SPESG
NASDAQ:NQUSLG
$282.68
−0.96%
At close
At close · Tue 20 Oct · ≈
AED 1,038.14
· Market cap
$499.53B
· Next earnings
Fri 30 Oct
· Extended
$285.24
+0.91%
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
AbbVie Inc · News · TradingHolo
ABBV news
Headlines tagged to this company
PR
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
PR Newswire · 13 d ago
GU
AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
GuruFocus · 14 d ago
DO
AbbVie Price Target Raised to $320.00/Share From $280.00 by Scotiabank
Dow Jones Newswires · 14 d ago
TR
Scotiabank maintains Sector Outperform rating on AbbVie, $320 price target
TradingView · 14 d ago
SH
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug
ShareCast · 14 d ago
RE
Global healthcare companies invest billions to boost US presence
Reuters · 14 d ago
DP
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL
dpa-AFX · 14 d ago
RE
Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Reuters · 15 d ago
RE
Abbvie - Q3 2026 GAAP And Adjusted Earnings Include $216 Million Bought Ipr&D And Milestones Expense - SEC Filing
Reuters · 15 d ago
SE
AbbVie flags $216M IPR&D and milestones expense for Q3
Seeking Alpha · 15 d ago
SE
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
Seeking Alpha · 15 d ago
RE
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Reuters · 15 d ago
BU
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
BusinessWire · 15 d ago
GL
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
GlobeNewswire · 15 d ago
SE
Regenxbio a new Outperform at Mizuho on potential of two pipeline drugs
Seeking Alpha · 15 d ago
SE
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
Seeking Alpha · 17 d ago
RE
AbbVie joins US government pilot to test drug discount rebates
Reuters · 18 d ago
SE
Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma
Seeking Alpha · 18 d ago
SE
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
Seeking Alpha · 18 d ago
RE
Major drugmakers turn to China for licensing deals
Reuters · 18 d ago
← Previous
More news →